The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Barclays Slashes Novo Nordisk's CagriSema Sales Forecast by 80%

Key Facts

1Barclays analysts slashed peak sales forecasts for the next-generation obesity drug CagriSema to $2 billion from $12 billion.

2The revision follows disappointing clinical trial results for the drug released a day earlier.

Barclays analysts have significantly downgraded their peak sales expectations for Novo Nordisk's next-generation obesity drug, CagriSema. The forecast was slashed from $12 billion to just $2 billion, representing a massive 83% reduction in projected revenue. This drastic revision follows disappointing clinical trial results released a day earlier, which failed to meet high market expectations. The poor performance of CagriSema in recent trials raises concerns about its competitive positioning in the high-growth weight-loss market. Analysts noted that the downgrade reflects a more cautious outlook on the drug's long-term commercial viability and pipeline strength. Consequently, the news has weighed on investor sentiment regarding Novo Nordisk's future valuation and its ability to maintain market leadership.